Randomised phase II trial comparing vinorelbine and capecitabine with docetaxel and capecitabine chemotherapy for metastatic breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN66842537

Enrollment

100

Registered

2003-09-12

Start date

2002-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Breast

Interventions

Randomisation will be stratified by previous anthracycline exposure. 1. Vinorelbine 25mg/m^2 intravenous (IV) 30 min DI + 8q 21 days. Capecitabine 1 g/m^2 orally, twice daily for 14 in every 21 days.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Metastatic breast cancer following initially histologically proven adenocarcinoma of the breast.

Exclusion criteria

Exclusion criteria: Exclusions include previous treatment with vinorelbine, docetaxel or capecitabine and presence of other primary cancers.

Design outcomes

Primary

Measure	Time frame
Toxicity, response and survival.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026